Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella Pharmaceuticals, Allergan, Ironwood Pharmaceuticals, Vaneltix Pharma, Prevail Infoworks
December 13, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Interstitial Cystitis Market to Accelerate Substantially by 2032, Predicts DelveInsight | Leading Companies - Integrative Therapeutics, Lipella...
Interstitial Cystitis Market to Receive Healthy Growth of USD 2,377.87 Million by 2029, Size, Share, Competitive Landscape, Regional Overview and Global Forecast
October 11, 2022 10:17 ET
|
Data Bridge Market Research
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- “Global Interstitial Cystitis Market” the new research report adds to Data Bridge Market Research’s reports database. This Research Report is spread across...
Solas BioVentures Co-Founder David Adair, M.D. Joins Mayfield Pharmaceuticals Board of Directors
October 23, 2019 07:30 ET
|
Harrow Health, Inc.
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced David Adair, M.D. will join the...
Mayfield Pharmaceuticals to Present at the SVB Leerink New Treatments Focused on Women’s Health Conference on October 10, 2019
October 08, 2019 07:35 ET
|
Harrow Health, Inc.
BOSTON, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Mayfield Pharmaceuticals, the women’s health-focused subsidiary of Harrow Health, Inc. (NASDAQ: HROW), today announced its Chief Executive Officer, Melissa...
Harrow Health Announces Launch of Mayfield Pharmaceuticals
July 31, 2019 07:30 ET
|
Harrow Health, Inc.
NASHVILLE, Tenn., July 31, 2019 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), today announced it has filed a Form 8-K with the Securities and Exchange Commission containing a corporate...
Aquinox to Present at LEERINK Partners 5th Annual Global Healthcare Conference
January 28, 2016 09:15 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 28, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
January 11, 2016 07:00 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted...
Aquinox Pharmaceuticals Announces Closing of Initial Public Offering
March 12, 2014 12:58 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 12, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (Nasdaq:AQXP) announced today the closing of its initial public offering of 4,830,000 shares of its...
Aquinox Pharmaceuticals Prices Initial Public Offering
March 07, 2014 09:00 ET
|
Neoleukin Therapeutics, Inc.
VANCOUVER, British Columbia, March 7, 2014 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a...